Document is current
Any future updates will be listed below
-
Authors
Hosoya, Hitomi
Carleton, Mia https://orcid.org/0000-0001-9993-9787
Tanaka, Kailee
Sworder, Brian
Syal, Shriya
Sahaf, Bita
Maltos, Alisha M. https://orcid.org/0000-0001-6631-481X
Silva, Oscar
Stehr, Henning
Hovanky, Vanna
Duran, George https://orcid.org/0000-0003-2692-3906
Zhang, Tian
Liedtke, Michaela
Arai, Sally
Iberri, David
Miklos, David https://orcid.org/0000-0003-0717-4305
Khodadoust, Michael S.
Sidana, Surbhi https://orcid.org/0000-0003-3288-7614
Kurtz, David M. https://orcid.org/0000-0002-6382-4651
- License Information
-
More Information
Article History
Received: 6 January 2024
Accepted: 15 January 2025
First Online: 20 February 2025
Competing interests
: B.J.S.: consultancy: Foresight Diagnostics. M.L.: advisory board/consulting for Janssen, BMS, and Kite. D.M.: patent: Pharmacyclics supporting ibrutinib for chronic graft-vs-host disease. Research funding and consultancy: Pharmacyclics, Kite Pharma, Adaptive Biotechnologies, Novartis, Juno Therapeutics, Celgene, Janssen Pharmaceuticals, Roche, Genentech, Precision Bioscience, Allogene and Miltenyi Biotec. M.S.K: research funding: Nutcracker Therapeutics, CRISPR Therapeutics; Consultancy: Daiichi Sankyo, Myeloid Therapeutics. S.S.: research funding: Magenta Therapeutics, BMS, Allogene, Janssen; Consultancy: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda. D.M.K.: patents: D.M.K. reports issued patents pertaining to ctDNA-MRD detection assigned to Stanford University and licensed to Foresight Diagnostics. Consultancy: Foresight Diagnostics, Roche, Genentech, and Adaptive Biotechnologies. Stock and Equity Ownership: D.M.K. reports equity ownership in Foresight Diagnostics. The remaining authors declare no competing interests.
